Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 44Neoplasm Metastasis 5Ovarian Neoplasms 2Neoplasms, Hormone-Dependent 2Carcinoma, Lobular 2Carcinoma, Ductal, Breast 2Advanced Breast Cancer 2Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Medullary cystic kidney disease 1 1Lymphoma, Non-Hodgkin 1Leiomyosarcoma 1Hormone-sensitive Metastatic Breast Cancer 1HER2-positive Breast Cancer 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Breast Neoplasm Malignant Female 1Breast Diseases 1Breast Cancer Metastatic 1

Interventions

atamestane 2Toremifene 2Letrozole 2Estrogen Receptor Modulators 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasms, Hormone-Dependent × Letrozole × Clear all
NCT00267553 2007-09-10

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

Intarcia Therapeutics

Phase 3 Terminated
200 enrolled
Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT00097344 2007-08-23

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Intarcia Therapeutics

Phase 3 Terminated
842 enrolled
Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡